- Home
- LCTX vs RCKT Comparison
LCTX vs RCKT Comparison
Compare LCTX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- RCKT
- Stock Information
- Founded
- LCTX 1990
- RCKT 1999
- Country
- LCTX United States
- RCKT United States
- Employees
- LCTX N/A
- RCKT N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- LCTX Health Care
- RCKT Health Care
- Exchange
- LCTX Nasdaq
- RCKT Nasdaq
- Market Cap
- LCTX 274.0M
- RCKT 328.6M
- IPO Year
- LCTX N/A
- RCKT N/A
- Fundamental
- Price
- LCTX $1.73
- RCKT $3.97
- Analyst Decision
- LCTX Strong Buy
- RCKT Buy
- Analyst Count
- LCTX 4
- RCKT 13
- Target Price
- LCTX $4.25
- RCKT $12.88
- AVG Volume (30 Days)
- LCTX 1.8M
- RCKT 3.1M
- Earning Date
- LCTX 11-13-2025
- RCKT 11-03-2025
- Dividend Yield
- LCTX N/A
- RCKT N/A
- EPS Growth
- LCTX N/A
- RCKT N/A
- EPS
- LCTX N/A
- RCKT N/A
- Revenue
- LCTX $10,914,000.00
- RCKT N/A
- Revenue This Year
- LCTX N/A
- RCKT N/A
- Revenue Next Year
- LCTX $176.00
- RCKT $3,592.75
- P/E Ratio
- LCTX N/A
- RCKT N/A
- Revenue Growth
- LCTX 76.43
- RCKT N/A
- 52 Week Low
- LCTX $0.37
- RCKT $2.19
- 52 Week High
- LCTX $1.85
- RCKT $18.17
- Technical
- Relative Strength Index (RSI)
- LCTX 62.37
- RCKT 56.54
- Support Level
- LCTX $1.53
- RCKT $3.67
- Resistance Level
- LCTX $1.77
- RCKT $4.06
- Average True Range (ATR)
- LCTX 0.10
- RCKT 0.27
- MACD
- LCTX -0.01
- RCKT 0.00
- Stochastic Oscillator
- LCTX 74.94
- RCKT 43.27
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.